[Clinical study with a new antihyperlipemic combination].
70 patients with hyperlipemias of various types were treated perorally with 350 mg Mg-chlorophenoxyisobutyrate, and 250 mg of mesoinositol-hexanicotinate (Atroplex) three times daily. This treatment led to a statistically significant decrease in the respective elevated serum lipid levels. The serum total cholesterol level was decreased by 20.3% in Type IIa and by 19.8% in Type IIb, the triglyceride level was decreased by 27.7% in Type IIb and by 38.9% in Type IV. The phosphatide level was lowered by 14.6% in Type IIa, by 15.7% in Type IIb and by 15.9% in Type IV; the cholesterol-phospholipid ratio could be shifted in favour of the phospholipids in Type IIa and IIb. Glucose tolerance and systolic blood pressure were not influenced, but in Type IV a statistically significant decrease in the diastolic pressure and in serum uric acid level was noticed. Prothrombine time and normal fibrinogen levels remained unchanged, elevated fibrinogen levels returned to normal. Elevations of serum enzymes and of serum bilirubin were noted which were minimal and reversible, liver toxicity could not be noticed. Subjective symptoms of peripheral circulatory disturbances improved markedly in 10 cases, the most striking side effect was the occurrence of gastrointestinal imcompatibility, which in one case forced to discontinue the medication. The dosage of the single components is this combined therapy is significantly lower than the doses usually used for clofibrate or mesoinositol-hexanicotinate.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D007294:Inositol / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010743:Phospholipids / Q000097:blood; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D004338:Drug Combinations; D009539:Nicotinic Acids; D010743:Phospholipids; D014280:Triglycerides; D014527:Uric Acid; D007294:Inositol; D002784:Cholesterol; D002994:Clofibrate
Klinische Studie mit einer neuen antihyperlipämischen Wirkstoffkombination